CTAD 2019
16
ASO score
Text
2/100
Reviews
0/100
Graphic
60/100
Other
0/100
App Rating
Votes
App Age
6y 1m
Last Update
Nov 27, 2019
Compare with Category Top Apps
|
Metrics
|
Current App
|
Category Top Average
|
Difference
|
|---|---|---|---|
|
Rating
|
0
|
4.6
|
|
|
Number of Ratings (Voted)
|
0
|
65.4K
|
|
|
App Age
|
6y 1m
|
9y 0m
|
-32%
|
|
In-app Purchases Price
|
$0
|
$35
|
|
|
Update Frequency
|
2229d
|
103d
|
+2 070%
|
|
Title Length
|
9
|
25
|
-64%
|
|
Subtitle Length
|
0
|
26
|
|
|
Description Length
|
1 483
|
2 675
|
-45%
|
|
Number of Screenshots
|
390
|
1385
|
-72
%
|
|
Size
|
70MB
|
281MB
|
-75
%
|
Category Ranking in United States
7 days
Last 7 days
Last 30 days
Last 90 days
Last 180 days
Last year
| Top | Dec 26, 2025 | Jan 02, 2026 |
|---|---|---|
|
No results were found!
|
||
| Top | Dec 26, 2025 | Jan 02, 2026 |
|---|---|---|
|
No results were found!
|
||
| Top | Dec 26, 2025 | Jan 02, 2026 |
|---|---|---|
|
No results were found!
|
||
| Top | Dec 26, 2025 | Jan 02, 2026 |
|---|---|---|
|
No results were found!
|
||
Ranking Keywords in United States
| Keywords | App Rank |
|---|
Analyze this and other apps using Asolytics tools
Text ASO
Title
(
Characters:
9
of 30
)
CTAD 2019
Subtitle
(
Characters:
0
of 30
)
Description
(
Characters:
1483
of 4000
)
The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.
Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.
The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We know of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Furthermore we also learned more of another pathway with Tau Biomarkers, and their implications for AD along with combination therapeutics and phase 3 clinical trials results. Again in 2019 Clinical teams will present their population studies on subjects in the early stage of the disease or even at the asymptomatic stage.
CTAD 2019 will highlight the latest on trying to get these trials off the ground.
Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments.}
Read more
Other
Additional Information
| Rating: | |
| Voted: | 0 |
| App Store Link: | |
| Website: | - |
| Email: | - |
| Privacy Policy: | |
| Categories: | Medical |
| Size: | 70MB |
| App Age: | 6 years 1 month |
| Release Date: | Nov 27, 2019 |
| Last Update: | Nov 27, 2019 |
| Version: | 1.0 |
Version history
1.0
Nov 27, 2019
